When Daniel Fischer cofounded Tevard Biosciences in 2017, he wasn’t trying to bet on the next hot RNA technology. His interest was more personal. His daughter Natasha has Dravet syndrome, a rare form ...

For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...

US-based biotechnology company Alltrna is developing transfer RNA (tRNA)-based therapies that aim to offer a broad solution for thousands of rare genetic diseases by targeting common mutations rather ...

A team of researchers led by University of California, Riverside biomedical scientists has identified a small, previously overlooked small RNA molecule that plays a major role in controlling the ...

Raghu R. Chivukula, MD, PhD, a physician-investigator in the Departments of Medicine & Surgery and the Center for Genomic Medicine at Massachusetts General Hospital and Harvard Medical School, is the ...

HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat hemophilia A. The Cambridge, Massachusetts-based biotech is closing “following ...

A team of researchers led by University of California, Riverside biomedical scientists has identified a small, previously ...

Alltrna is the latest in a growing number of startups with plans to develop therapies based on transfer RNA (tRNA), a family of RNA molecules that play a vital role in building proteins. The Cambridge ...

The study's main contributors include (L-R) graduate student Joshua Shaffer, professor Upasna Sharma, and postdoc Alka Gupta. (Photo by Carolyn Lagattuta) The pioneering research of UC Santa Cruz’s ...

Gene editing can repair mutations that prematurely halt protein synthesis, resulting in incomplete peptides that cause various diseases. However, other approaches achieve the same effect without ...